Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients
2006; Lippincott Williams & Wilkins; Volume: 20; Issue: 12 Linguagem: Inglês
10.1097/01.aids.0000238418.43937.3b
ISSN1473-5571
AutoresBlai Coll, Gerard Aragonès, Sandra Parra, Carlos Alonso‐Villaverde, L. Masana,
Tópico(s)Lipoproteins and Cardiovascular Health
ResumoWe tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.
Referência(s)